MedTrace Logo

Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke

NCT01778335 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 316

Last updated 2015-03-23

No results posted yet for this study

Summary

The purpose of the study is to understand whether a new treatment of stroke - endovascular clot removal - can be added to the current standard of care to improve patient outcomes.

All patients will receive the best standard stroke treatment. This includes treating patients with the clot dissolving drug tPA (tissue plasminogen activator). However, t-PA does not work in some patients and others are not eligible to receive t-PA because they present too late for treatment (they woke up with their stroke symptoms or their stroke was not witnessed).

During endovascular revascularization the blockage in the artery is removed with the use of devices called stentreivers and or by giving clot dissolving drug at the site of the blockage in the artery to restore blood flow. Stentrievers are devices that have been designed by different companies to remove blood clots from arteries.

Up to a maximum of 500 people at 20-25 hospitals across Canada and other countries will participate in this study.

Conditions

Interventions

PROCEDURE

Endovascular thrombectomy/thrombolysis

Endovascular mechanical thrombectomy or thrombolysis

Sponsors & Collaborators

  • Medtronic - MITG

    collaborator INDUSTRY

  • Heart and Stroke Foundation of Canada

    collaborator OTHER

  • Hotchkiss Brain Institute, University of Calgary

    collaborator OTHER

  • University of Calgary

    lead OTHER

Principal Investigators

  • MIchael D Hill, MD MSc FRCPC · University of Calgary

  • Andrew M Demchuk, MD FRCPC · University of Calgary

  • Mayank Goyal, MD FRCPC · University of Calgary

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2014-11-30
Completion
2015-01-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01778335 on ClinicalTrials.gov